{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.71","value":"3486.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Day 1, Cycle 1,n=28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.52","value":"5799.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Day 1, Cycle 2,n=18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"103.79","value":"6184.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Day 1, Cycle 4,n=12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (MM)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Part 2 MM Population comprised of Part 2 MM participants of All Treated Population who had atleast 1 non-missing (NQ) PK assessment. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)","title":"Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}